Skinvisible

Skinvisible CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Skinvisible (SKVI) as of Oct 20, 2026 is -10.64 %. In the previous year, CapEx to Operating Cash Flow Ratio was -13.20 % — a change of -19.41% (higher).

CapEx/OCF

-10.64 %

YoY

-19.41%

Last updated:

CapEx to Operating Cash Flow Ratio of Skinvisible is 2025 -10.64 % . CapEx to Operating Cash Flow Ratio of Skinvisible was 2024 -13.20 % . It decreases by -19.41% higher compared to the previous year.

The Skinvisible CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-33.54 USD
Jan 1, 2019
-1.65 USD
Jan 1, 2020
36.64 USD
Jan 1, 2021
0.68 USD
Jan 1, 2022
5.60 USD
Jan 1, 2023
-12.10 USD
Jan 1, 2024
-13.20 USD
Jan 1, 2025
-10.64 USD
The Skinvisible CapEx/OCF history
YEARCapEx/OCFYoY
-10.64 %-19.41%
-13.20 %+9.12%
-12.10 %-315.96%
5.60 %+729.32%
0.68 %-98.16%
36.64 %-2,327.07%
-1.65 %-95.09%
-33.54 %-68.99%
-108.14 %+1,661.31%
-6.14 %+814.39%
-0.67 %-88.96%
-6.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Skinvisible stock

CapEx to Operating Cash Flow Ratio of Skinvisible is -10.64 % in 2025.

CapEx to Operating Cash Flow Ratio of Skinvisible changed from -13.20 % to -10.64 %, representing a -19.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Skinvisible since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Skinvisible with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Skinvisible

All Key Metrics — Skinvisible